0734 GMT - Novartis's 2025 guidance signals a slowdown in the growth outlook as patent expiries begin and pipeline catalysts are lacking, Berenberg analyst Kerry Holford says in a note. "In our view, Novartis is fully valued, pricing in a positive pipeline regeneration gap, which we struggle to support given its poor historical returns on R&D investment," she says. The Swiss pharma company will release a late-stage trial of its treatment for Sjogren's syndrome in the second half of the year, Holford says. However, more significant results are expected next year, such as the late-stage trial of cardiovascular disease prevention pelacarsen and thrombosis treatment abelacimab, the analyst says. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
March 17, 2025 03:34 ET (07:34 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。